218 related articles for article (PubMed ID: 3021253)
1. Interaction of a bovine thymic peptide extract with vasoactive intestinal peptide (VIP) receptors.
Guerrero JM; Goberna R; Molinero P; Jimenez J; Calvo JR
Biosci Rep; 1986 Jun; 6(6):579-84. PubMed ID: 3021253
[TBL] [Abstract][Full Text] [Related]
2. Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.
Calvo JR; Goberna R; Guerrero JM
Biosci Rep; 1986 Aug; 6(8):727-33. PubMed ID: 3028522
[TBL] [Abstract][Full Text] [Related]
3. Effect of freezing on the coupling of VIP receptors to adenylate cyclase in rat liver membranes.
Robberecht P; Waelbroeck M; De Neef P; Camus JC; Gourlet P; Christophe J
Life Sci; 1988; 42(5):505-10. PubMed ID: 2828794
[TBL] [Abstract][Full Text] [Related]
4. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
[TBL] [Abstract][Full Text] [Related]
5. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Gila monster venom with VIP receptors in intestinal epithelium of human. A comparison with rat.
Amiranoff B; Vauclin-Jacques N; Boige N; Rouyer-Fessard C; Laburthe M
FEBS Lett; 1983 Dec; 164(2):299-302. PubMed ID: 6317454
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
RodrÃguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
8. Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium.
Rouyer-Fessard C; Couvineau A; Voisin T; Laburthe M
Life Sci; 1989; 45(9):829-33. PubMed ID: 2549322
[TBL] [Abstract][Full Text] [Related]
9. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29.
Turner JT; Jones SB; Bylund DB
Peptides; 1986; 7(5):849-54. PubMed ID: 3025826
[TBL] [Abstract][Full Text] [Related]
10. Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.
Waelbroeck M; Robberecht P; De Neef P; Chatelain P; Christophe J
Biochim Biophys Acta; 1981 Nov; 678(1):83-90. PubMed ID: 6272875
[TBL] [Abstract][Full Text] [Related]
11. Effector mechanisms of peptides of the VIP family.
Christophe J; Svoboda M; Lambert M; Waelbroeck M; Winand J; Dehaye JP; Vandermeers-Piret MC; Vandermeers A; Robberecht P
Peptides; 1986; 7 Suppl 1():101-7. PubMed ID: 3018687
[TBL] [Abstract][Full Text] [Related]
12. Properties of vasoactive-intestinal-peptide receptors and beta-adrenoceptors in the murine radiation leukemia-virus-induced lymphoma cell line BL/VL3.
Abello J; Damien C; De Neef P; Tastenoy M; Hooghe R; Robberecht P; Christophe J
Eur J Biochem; 1989 Aug; 183(2):263-7. PubMed ID: 2547606
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of the adenylyl cyclase activity in human endometrial membranes by VIP and related peptides.
Bajo AM; Guijarro LG; Juarranz MG; Valenzuela P; Martinez P; Prieto JC
Biosci Rep; 1993 Apr; 13(2):69-77. PubMed ID: 8397008
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
[TBL] [Abstract][Full Text] [Related]
15. PACAP and VIP receptors in rat liver membranes.
Robberecht P; Gourlet P; Cauvin A; Buscail L; De Neef P; Arimura A; Christophe J
Am J Physiol; 1991 Jan; 260(1 Pt 1):G97-102. PubMed ID: 1846275
[TBL] [Abstract][Full Text] [Related]
16. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol modulation of membrane fluidity and VIP receptor/effector system in rat prostatic epithelial cells.
Carmena MJ; Hueso C; Guijarro LG; Prieto JC
Regul Pept; 1991 May; 33(3):287-97. PubMed ID: 1652781
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide receptors in rat liver after partial hepatectomy.
Guijarro LG; Couvineau A; Rodriguez-Pena MS; Juarranz MG; Rodriguez-Henche N; Arilla E; Laburthe M; Prieto JC
Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):515-20. PubMed ID: 1322136
[TBL] [Abstract][Full Text] [Related]
19. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
Gespach C; Bawab W; de Cremoux P; Calvo F
Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
